Status:
COMPLETED
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
Lead Sponsor:
AstraZeneca
Conditions:
Gastrointestinal Stromal Tumors
Soft Tissue Sarcomas
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesyla...
Eligibility Criteria
Inclusion
- Histological or cytological confirmation of GIST which is resistant or intolerant to imatinib mesylate, or metastatic STS, which is refractory to standard therapies or for which no standard therapy exists
Exclusion
- Patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-independent diabetes.
- Patients with a history of poorly controlled high blood pressure
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00385203
Start Date
September 1 2006
End Date
December 1 2009
Last Update
July 16 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Manchester, United Kingdom
2
Research Site
Sutton, United Kingdom